Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Research Resources (NCRR)
• Treatments: Nifedipine

Criteria

Inclusion Criteria:

• diagnosed with Congenital Adrenal Hyperplasia (CAH)

• normal ECG during baseline evaluation

Exclusion Criteria:

• history of liver disease, or elevated liver function tests

• history of cardiovascular disease